Kansas Drugs & Pharmaceuticals.Ltd. Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 17-12-2024
- Paid Up Capital ₹ 0.15 M
as on 17-12-2024
- Company Age 33 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.73 Cr
as on 17-12-2024
- Revenue 26.50%
(FY 2022)
- Profit 35.90%
(FY 2022)
- Ebitda 28.72%
(FY 2022)
- Net Worth 15.19%
(FY 2022)
- Total Assets 10.65%
(FY 2022)
About Kansas Drugs & Pharmaceuticals.Ltd.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.15 M.
The company has closed loans amounting to ₹1.73 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Anil Shah, Dipak Shah, and Neerav Shah serve as directors at the Company.
- CIN/LLPIN
U24232WB1991PTC050766
- Company No.
050766
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jan 1991
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kansas Drugs & Pharmaceuticals.Ltd.?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Shah  | Director | 28-Jan-1991 | Current |
| Dipak Shah | Director | 28-Jan-1991 | Current |
| Neerav Shah | Director | 15-Sep-2023 | Current |
Financial Performance of Kansas Drugs & Pharmaceuticals.Ltd..
Kansas Drugs & Pharmaceuticals Pvt.Ltd., for the financial year ended 2022, experienced significant growth in revenue, with a 26.5% increase. The company also saw a substantial improvement in profitability, with a 35.9% increase in profit. The company's net worth Soared by an impressive increase of 15.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kansas Drugs & Pharmaceuticals.Ltd.?
In 2020, Kansas Drugs & Pharmaceuticals.Ltd. had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Kansas Laboratories Pvt LtdActive 38 years 1 monthAnil Shah, Dipak Shah and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 22 Nov 2006 | ₹1.73 Cr | Satisfied |
How Many Employees Work at Kansas Drugs & Pharmaceuticals.Ltd.?
Unlock and access historical data on people associated with Kansas Drugs & Pharmaceuticals.Ltd., such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kansas Drugs & Pharmaceuticals.Ltd., offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kansas Drugs & Pharmaceuticals.Ltd.'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
